Trials / Completed
CompletedNCT05096962
COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
SARS-CoV-2-CZ-PREVAL-II Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,268 (actual)
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific subjects cohorts.
Detailed description
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in four specific cohorts: participants with chronic illness, healthy volunteers participating in the Study of the Czech Academy of Science, healthcare workers, and healthy volunteers that participated in the "Herd Immunity Study SARS-CoV-2-CZ-Preval" in May 2020. The primary aim of the study is to estimate the number of people with anti-SARS-CoV-2-antibodies, i.e., people with COVID-19 history, or with vaccination against COVID-19. Antibodies test will focus on two main proteins of virus SARS-CoV-2: S-protein and N-protein. The secondary aims of the study are: * quantitative analysis of cellular immunity and the other relevant markers, * estimation of the proportion of participants with asymptomatic COVID-19 infection * quantification of anti-SARS-CoV-2 antibodies and cell immunity according to individual risk factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Quantitative analysis of SARS-CoV-2 antibodies | The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein). |
| DIAGNOSTIC_TEST | Cellular immunity | Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals. |
Timeline
- Start date
- 2021-09-13
- Primary completion
- 2021-10-31
- Completion
- 2022-02-24
- First posted
- 2021-10-27
- Last updated
- 2022-11-28
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT05096962. Inclusion in this directory is not an endorsement.